A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer
Status:
Not yet recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
Evaluate efficacy and safety of SHR-1701 in combination with bevacizumab and chemotherapy in
advanced or metastatic non-squamous non-small-cell lung cancer with EGFR mutation after
failure of TKIs